rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Nicholas Maestas

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Rani Therapeutics Holdings; Chief Financial Officer, Tempest Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
11
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
2
Companies where not an officer
0
First trade
12 Jul 2021
Last trade
17 Jul 2026
Last filed
21 Jul 2026

Companies traded

Where they are an officer
RANI Rani Therapeutics HoldingsOfficer · Biotechnology · last 17 Jul 20260 buys · 0 sells
TPST Tempest TherapeuticsOfficer · Biotechnology · last 31 Mar 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
17 Jul 2026filed 21 Jul 2026RANI Rani Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—2,000,000 at $0.00filing
17 Jul 2026filed 21 Jul 2026RANI Rani Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—2,000,000 at $0.00filing
31 Mar 2026filed 2 Apr 2026TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—140,000 at $0.00filing
31 Mar 2026filed 2 Apr 2026TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—140,000 at $0.00filing
2 Jan 2025filed 6 Jan 2025TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—200,000 at $0.00filing
3 Jan 2024filed 5 Jan 2024TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
11 Oct 2023filed 13 Oct 2023TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—100,000 at $0.00filing
3 Jan 2023filed 5 Jan 2023TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—38,425 at $0.00filing
21 Jun 2022filed 22 Jun 2022TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—51,270 at $0.00filing
4 Jan 2022filed 6 Jan 2022TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,500 at $0.00filing
12 Jul 2021filed 14 Jul 2021TPST Tempest Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—23,225 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Nancy Freda SmithDirector · Director at Tempest Therapeutics, filing Form 4 there in the last year
Alireza JavadiChief Technical Officer · Chief Technical Officer at Rani Therapeutics Holdings, filing Form 4 there in the last year
Talat ImranChief Executive Officer · Chief Executive Officer at Rani Therapeutics Holdings, filing Form 4 there in the last year
Michelle GilsonDirector · Director at Rani Therapeutics Holdings, filing Form 4 there in the last year
Mir A. ImranDirector and 10% owner · Director and 10% owner at Rani Therapeutics Holdings, filing Form 4 there in the last year